BAT5906 vs Tarcocimab tedromer
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
BAT5906
Developed by Bio-Thera Solutions
NCT05439629 · Phase 3 · completed
The study randomized 488 participants to BAT5906 or active treatment with Lucentis and masked participants, care providers, and investigators. Its primary outcomes were clinical measures of visual acuity, but the registry does not report whether the comparison was favorable or statistically significant, so the evidence remains limited pending results.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
No aligned efficacy figure on record for this race.
Tarcocimab tedromer
Developed by Kodiak Sciences Inc.
NCT06556368 · Phase 3 · active, not recruiting
This was a randomized, quadruple-masked Phase 3 trial with 675 participants. Its primary endpoint was met according to the sponsor's announcement of 2026-09-28. The result comes from the sponsor's announcement and the sources read give no power calculation, so the grade is moderate.
Reported efficacy
Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): Mean Change in Best Corrected Visual Acuity (BCVA) From Day 1 to the Average of Non-missing BCVA Values of Weeks 40, 44 and 48. (Day 1 to Week 48): KSI-301 (Treatment Group A) 2.5 ETDRS Letters (Standard Error 0.78) vs Aflibercept (Treatment Group B) 4.6 ETDRS Letters (Standard Error 0.76) (met)
Result source: NCT04964089
Results for Age-Related Macular Degeneration
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
BAT5906: no structured comparison results are available for Age-Related Macular Degeneration.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tarcocimab tedromer
+ 68 further endpoints in the CSV export.
Available safety results
Tarcocimab tedromer
| Dropout rate | 8.3% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
|---|---|
| Discontinued due to AEs | 2.9% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Serious AEs | 14.1% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
| Most frequent reported AEs | covid-19 12.3% neovascular age-related macular degeneration - fellow eye 8% vitreous floaters - study eye 7.6% NCT04964089 · Phase 3 · monotherapy · Age-Related Macular Degeneration, Wet Age-Related Macular Degeneration · phase 3 |
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BAT5906's landscape · Tarcocimab tedromer's landscape